Company: ANIX
Filing Date: 2025-02-06
Form Type: DEF 14A
Source: 0001493152-25-005199
Chunk: 36

Company: Anixa Biosciences Inc
Filing Date: 2025-02-06
Form: DEF 14A
Chunk 36
---
DIRECTORS’ COMPENSATION</div>

| Name                    |     | Cash |        |     | Option         
 Awards  (1)(2) |        |     | Total        
 Compensation |         |
|:------------------------|:----|:-----|-------:|:----|:---------------|-------:|:----|:-------------|--------:|
| Lewis H. Titterton, Jr. |     | $    | 95,000 |     | $              | 72,675 |     | $            | 167,675 |
| Dr. Arnold Baskies      |     | $    | 95,000 |     | $              | 72,675 |     | $            | 167,675 |
| Emily Gottschalk        |     | $    | 95,000 |     | $              | 72,675 |     | $            | 167,675 |

| (1) | These amounts have been                                                                                                                   
 calculated in accordance with ASC 718. A discussion of assumptions used in valuation of option awards may be found in Note 2 to our       
 Consolidated Financial Statements for fiscal year ended October 31, 2024, included in our Annual Report on Form 10-K. These amounts       
 reflect our accounting expense for these stock options and do not correspond to the actual value that may be recognized by our directors. |
| (2) | At October 31, 2024, Mr.                                                                                                                  
 Titterton, Dr. Baskies and Ms. Gottschalk held unexercised stock options to purchase 827,000, 338,000 and 255,000 shares respectively,    
 of our common stock.                                                                                                                      |

| 24 |

<div align='center'>PROPOSAL 2

APPROVAL ON AN ADVISORY BASIS OF THE COMPENSATION OF NAMED EXECUTIVE OFFICERS</div>

Introduction

In accordance with Section 951 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (the “Dodd-Frank Act”) and Section 14A of the Exchange Act, the following proposal, commonly known as a “Say on Pay” proposal, enables our stockholders to vote to approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in this proxy statement in accordance with applicable SEC rules.

Our goal for our executive compensation program is to attract, motivate and retain a talented team of executives who will provide leadership